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Reprogramming of somatic cells into induced pluripotent stem
cells (iPSCs) and their differentiation into neural lineages is a revolutionary experimental system for studying neurological disorders, including intellectual and developmental disabilities
(IDDs). However, issues related to variability and reproducibility
have hindered translating preclinical findings into drug discovery.
Here, we identify areas for improvement by conducting a comprehensive review of 58 research articles that utilized iPSC-derived
neural cells to investigate genetically defined IDDs. Based upon
these findings, we propose recommendations for best practices
that can be adopted by research scientists as well as journal editors.

Introduction
In the United States, ~3%–4% of children are diagnosed
with intellectual and developmental disabilities (IDDs)
annually (Zablotsky et al., 2017). Many IDDs are associated
with genetic conditions, including Down syndrome, fragile X syndrome, Rett syndrome, tuberous sclerosis, Dravet
syndrome, Williams syndrome, Angelman syndrome, and
copy-number variants (CNVs), including 22q13.3, 15q11q13.1, and 16p11.2. Human pluripotent stem cells (hPSCs)
provide an essential tool to understand alterations that
occur during this inaccessible period of prenatal brain
development. Specifically, induced pluripotent stem cells
(iPSCs) derived from patient somatic cells can recapitulate
in vitro developmental steps that may be disrupted during
brain development in vivo. iPSC-derived neuronal and glial
cells retain genetic contributors to IDDs present in the
patient from whom they were derived, reveal altered development and/or function that may contribute to IDDs.
iPSC-derived cells also provide platforms for chemical and
molecular screening to identify novel therapeutic targets
for IDD-related neurodevelopmental abnormalities, potentially leading to new treatments.
To assess progress in IDD research, we identified 249
PubMed articles investigating IDDs published from 2010
to 2018 (Figure 1; Table S1) using the listed search
terms (supplemental information). Papers were manually
screened to include only primary literature involving

both generation of patient-derived iPSCs and neuronal
cell differentiation, which narrowed the final list to 58 papers. Each paper was evaluated based upon information
supplied in the manuscript and the supplemental information and given an overall ‘‘quality score’’ based upon
several categories (Table S1). We did not include numbers
of lines or of patients studied as criteria for scoring, because
these parameters are often study design dependent and
thus cannot readily be evaluated in a quantitative, objective manner. Each publication was evaluated on a scale of
0–23, with 0 as the lowest and 23 the highest possible score
(Table S1; supplemental information). Evaluation categories were based on scientific guidelines for lab resources
published by Stem Cell Research and the STAR Methods
(structured, transparent, accessible reporting) published
by Cell Press. The analyses performed here are by no means
exhaustive and did not incorporate articles that solely
generated iPSCs from IDD patients or solely differentiated
and characterized neural cells to study IDD.
Among the 58 papers reviewed, scores ranged from 8 to 20
(median = 16; mean = 15.43, Figure 1A). The distribution is
relatively symmetric with a negative skew (Figure S1A), as expected because we selected standard, common scoring practices. To better compare overall publication quality
over time, we divided the 58 primary articles into 2 subgroups—articles published between 2010 and 2014 (n = 28)
and between 2015 and 2018 (n = 30). This analysis identified
a downward trend in publication quality over time that did
not reach statistical significance (Figure 2A). Interestingly,
this trend is primarily driven by a significant decline in
reported information related to iPSC derivation and QC
assessment (Figures 1B and 2B). However, recent papers often
utilize more patients and/or more iPSC lines, as indicated by
the color and size of each data point (Figure 1). While this
may influence the QC performed/reported on each line,
the trend toward using more patients and iPSC lines to study
IDD is generally encouraging. We did not observe a significant score change over time for the category of experimental

1446 Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021 j ª 2021 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Stem Cell Reports
Perspective

Figure 1. Publication quality over time
Review and scoring of 58 primary articles published between 2010 and 2018 (x axis) utilizing iPSCs to investigate genetically defined IDDs.
(A) Each publication was scored on a scale of 0–23 (y axis) and arranged in chronological order (x axis).
(B) iPSC derivation and quality controls were scored on a scale of 0–8 (y axis) and arranged in chronological order (x axis). For graphs for
the other two categories, see Figure S1. Numbers of iPSC lines and patients modeled is indicated by the size and color of the circles,
respectively. A smooth regression line (blue) and confidence band (gray shade) are shown using geom_smooth function through ggplot2
in R.
design and background information, nor for the neural differentiation and QC categories (Figures S1B and S1C).
Numerous factors could contribute to a decline in iPSC
derivation and QC assays reported: (1) as iPSC technology
becomes more established, less emphasis is placed on best
practices for culture and systematic QC; (2) increased
numbers of iPSC lines and clones create challenges in
balancing the large amount of work and resources needed
to conduct both QC and hypothesis-driven experiments;
(3) laboratories often use previously published protocols,
but fail to detail modifications; and (4) space for experimental detail and QC data may be limited by journals.
We posit that these factors contribute to decreased publication quality and diminished cross-site reproducibility (Volpato et al., 2018). It is unclear to what extent biological
differences, technical differences driven by differentiation
methods, inconsistent QC and culturing practices, choices
of controls, or all of the above, contribute to discrepancies
in data from iPSC studies of IDDs. Furthermore, although
compelling evidence for altered glial development in
IDDs has been reported recently (Cresto et al., 2019;
Wong, 2019), this analysis focuses on neural progenitor
cells (NPCs) and/or cortical neurons, as these remain the
focus of most current IDD-related studies. Literature related
to glial differentiation of iPSCs and IDD studies in iPSCderived glia is presented in Table S2. Here, we highlight
key biological and technical variables that may contribute
to decreased cross-site reproducibility of iPSC-based IDD
studies. Importantly, we provide recommendations to

improve transparency and reproducibility, so that findings
have greater impact for patients and families affected by
IDDs (Table 1).
Biological considerations for studying IDDs in patient-derived
iPSCs
iPSC-derived neural cells provide a powerful human experimental system to study how IDD-contributory genetic
mutations alter neurodevelopment, yet challenges exist.
iPSC-derived neural cells are best suited to analyzing
cellular and molecular mechanisms that contribute to
IDDs and are less useful for network and systems level inquiry, given the lack of synaptic maturation and the
absence of some cell types found in vivo. Investigating phenotypes that can be recapitulated with iPSC-derived
neurons (e.g., oxidative stress) is hampered by biological
variability, as discussed below. Nonetheless, iPSC models
can effectively be used to study both syndromic IDDs
attributed to single gene mutations (Deneault et al., 2019;
Deshpande et al., 2017; Griesi-Oliveira et al., 2015; Wang
et al., 2017) and subjects with IDDs of unknown etiology
but with shared phenotypic characteristics, such as macrocephaly (Marchetto et al., 2017; Mariani et al., 2015; Schafer et al., 2019).
Genetic heterogeneity of human subjects
Unlike animal experimental systems, which are generally
inbred, genetic variation between iPSC lines is a challenge
linked to the inherent genetic variability among humans.
Strategies can minimize the effect of genetic background
in iPSCs, which may lessen variability at a cellular and
Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021 1447
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Figure 2. Score distribution analysis of publication quality
(A) Overall score distribution (x axis) of 58
primary articles published from 2010 to 2014
(n = 28, red) or 2015 to 2018 (n = 30, turquoise). Dashed lines in corresponding colors
indicate mean scores of 16.07 and 14.83,
respectively (p = 0.08087).
(B) Score distributions (x axis) and comparison
between the two groups of articles for each
main category evaluated: iPSC derivation and
QC (top, p = 0.00958), experimental design,
background information (center, p = 0.53114),
and neuronal differentiation and quality control (bottom, p = 0.80436). p values determined by two-sample t testing.

molecular level. First, the number of individuals from
whom samples are obtained must be considered. Power
analysis to calculate the needed sample size for an expected
effect size is challenging, due to difficulties in defining both
the level of heterogeneity and effect size of molecular and
cellular phenotypes (Hoekstra et al., 2017). For example,
a sample size of five gives a power ratio of 0.5 if heterogeneity is low. However, as heterogeneity increases, so does the
ideal sample size (e.g., >10 individuals per group). Unfortunately, simply increasing sample size is not feasible for
many studies, given the enormous time and cost associated
with this work, as well as limited patient availability for rare
IDDs. Second, selecting control individuals is critical.
Many iPSC-based studies choose controls based solely on
lack of diagnosis and age and/or sex match. Yet, this simple
design does not account for underlying genetic heterogeneity that may contribute to phenotypes. Controls that
include non-affected family members with partially shared
genetic backgrounds can lessen effects of this underlying
genetic variation.
Challenges in distinguishing biologically relevant
cellular phenotypes that contribute to IDD-related traits
versus those resulting from individual variability between
patients’ genetic backgrounds can also be addressed by using isogenic control cells. For monogenic disorders,
isogenic controls can be generated through CRISPR-Cas9based gene editing of iPSCs, to correct an IDD-related mutation in patient-derived cells, or introduce the mutation
1448 Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021

into control cells. While CRISPR-based gene editing can
introduce unwanted off-target changes in the genome,
analysis has shown low rates of unwanted changes in
gene-edited hPSCs (Smith et al., 2014, 2015). To reduce
the likelihood of these confounding effects, alternative editing systems, including Cas9 variants with enhanced specificity or systems foregoing double-strand DNA breaks can
be used (Table S3) (Chaudhari et al., 2020). It is also feasible
to sequence the genome of engineered lines at reasonable
cost to detect such changes (Banan, 2020; Broeders et al.,
2020). However, gene-editing technology cannot currently
correct disorders involving multiple genes or large mutations (e.g., CNVs). An alternative strategy involves recruiting mosaic individuals for iPSC generation. Somatic cells in
mosaic individuals all derive from a single zygote and thus
are genetically identical, except for the presence or absence
of the mutation. iPSCs derived from mosaic individuals are
particularly valuable if mosaicism arose early in development, because cells with and without the mutation have
gone through similar developmental processes in vivo.
Isogenic controls provide a powerful tool to validate disease-related phenotypes in iPSC-based experimental
systems.
Cell line variability
While iPSCs resemble human embryonic stem cells
(hESCs), their distinct source must be considered. Variability may arise in either the somatic cell of origin or
reprogramming method. The contribution of different
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Table 1. Recommendations for characterizing iPSCs, NPCs, and neurons include molecular, cellular, and functional methods with
the goal of improving reproducibility in iPSC culture and differentiation.

Molecular and cellular

iPSC
characterization

NPC
characterization

Neuronal
characterization

G-banded karyotyping

–

–

KaryoStat assays

–

–

STR profiling

–

–

hPSC genetic analysis kit

–

–

SNP microarray

–

–

RNA sequencing

RNA sequencing

RNA sequencing

RT-PCR: OCT4, Nanog, SSEA3/4

RT-PCR: Sox2, Nestin, Pax6,
vimentin

RT-PCR: TUBB3, NeuN, MAP2,
neuronal subtype specific genes

mycoplasma/sterility

sterility

sterility

immunostaining

immunostaining

immunostaining

cell source

–

–

reprogramming method

–

–

number of clones (patients, controls)

–

–

cell line gender

–

–

patient demographic info

–

–

morphology (presence of spontaneously
differentiating cells)

–

–

passaging method

–

–

media composition

media composition

media composition

extracellular matrix

extracellular matrix

extracellular matrix

seeding density for differentiation

seeding density

seeding density

passage number

passage number

–

–

technical repeats

technical repeats

–

–

differentiation method

embryoid body formation followed by
trilineage qPCR

–

neurite outgrowth

teratoma formation (optional)

–

morphometric analysis

–

–

multi-electrode array

–

–

electrophysiology (number of neurons)

–

–

calcium transients (number of regions of
interest)

CNV qPCR assays and arrays

Technical

Functional

derivation methods to genetic or epigenetic variability of
iPSC lines has not been systematically assessed. However,
researchers generally agree that reprogramming methods
that avoid genome integration are preferred. Clonal iPSC

lines generated by reprogramming can exhibit variable
morphology, proliferation rates, stem cell marker expression, and differentiation potential (Hu et al., 2010). To
study IDD-related developmental deficits, iPSCs must
Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021 1449
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readily differentiate into neural cell types. Newly generated
iPSC lines can be screened for robust neural differentiation
potential, as measured by frequencies of iPSC-derived NPCs
expressing PAX6 and/or SOX2, excluding poorly differentiating clones (e.g., <80% PAX6+/SOX2+ NPCs) from further
work. Alternatively, expression of specific microRNAs distinguishes iPSC lines with differential neurogenic differentiation propensity (Du et al., 2013). Multiple clonal lines
should be characterized to identify the best clones for
experimental use.
Two technical variables that influence iPSC performance
are the maintenance media and use of feeder-free culture
versus culture on mouse embryonic fibroblast (MEF) feeder
layers. Initial protocols involved culture on MEF feeders in
media containing 20% serum. However, as serum composition is not controlled and exhibits lot-to-lot variability,
alternatives include serum-free media of defined composition (e.g., knockout serum replacement plus basic fibroblast growth factor [bFGF]). Currently, feeder-free culture
in defined media, such as mTeSR (STEMCELL Technologies)
and on Matrigel (Hannoun et al., 2010; Inzunza et al.,
2005; Ludwig and Thomson, 2007; Thomson et al., 1998)
lessen both variability and labor. A survey of the IDDRC
Human Stem Cell Working Group established that all centers currently culture iPSCs under feeder-free conditions,
with 12 of the 13 groups using Matrigel (or equivalent) substrate. Three groups also use MEF feeder layers routinely.
The predominant use of Matrigel-like substrates versus human recombinant substrates (e.g., vitronectin or rhLaminin-521), likely reflects their widespread availability from
commercial sources and relative affordability. The effect
of different feeder conditions is poorly understood, as
suggested by recent findings of differences in organoid production between iPSCs cultured under different feeder conditions (Watanabe et al., 2019). Heat-stabilized bFGF can
reduce fluctuations in cell signaling and spontaneous differentiation (Daniszewski et al., 2018; Lotz et al., 2013).
Studies have assessed specific aspects of iPSC culture,
including effects of different maintenance media on gene
expression (Daniszewski et al., 2018) and of different somatic cells of origin on motor neuron differentiation (Bardelli et al., 2020). Systematic, comprehensive review and
meta-analysis will be needed to understand how iPSC derivation methods and/or culture conditions affect neural
differentiation. Given the large number of independent
variables, extensive cross-site collaborative efforts may be
necessary to assess their relative contributions.
Development of human cortical neurons
Balanced inhibitory and excitatory neuronal activity in the
cerebral cortex is needed for normal neurological function
and often disrupted in IDDs, due to altered development
and/or function of either or both neuronal subtypes. Therefore, many IDD cell-based experimental approaches focus
1450 Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021

on mimicking aspects of these developmental programs.
During cortical development, progenitors generate
different neuronal layers at distinct developmental stages.
Excitatory glutamatergic projection neurons are derived
from the cortex in the dorsal forebrain, while inhibitory
GABAergic cortical interneurons originate from the subcortical ventral forebrain. Excitatory neurons arise from progenitor cells in the cortical ventricular zone and migrate
radially to their cortical layer destination, with early-generated neurons residing in deep layers, while late-generated
neurons reside in upper layers. During cortical progenitor
differentiation from iPSCs, this temporal sequence of
neuron specification is conserved (Anderson and Vanderhaeghen, 2014; Gaspard et al., 2008), such that differentiating upper layer cortical neurons can take several months.
Each temporally defined progenitor population can be
differentiated into layer-specific neurons by inhibiting
cell division to synchronize differentiation (Borghese
et al., 2010; Ogura et al., 2013). This characteristic can be
exploited in study design to focus on the most relevant
neuronal subtypes affected in patients with a specific
IDD. Initial iPSC studies used differentiation protocols
that led to mixtures of primarily deep-layer GABAergic
and glutamatergic neurons. However, as many IDDs affect
upper layer neurons and interneurons, these studies may
have overlooked disorder-related phenotypes or implicated
phenotypes not relevant to IDD etiology. While protocols
for generating spinal motor neurons, dopaminergic neurons, and cortical excitatory and inhibitory neurons are
well developed, differentiation of other IDD relevant
neurons, such as hippocampal, serotonergic, and hypothalamic neurons, is not yet well established. Programs for
generating glial cells, including astrocytes and oligodendrocytes, have also been developed, but are used less extensively in IDD studies. Furthermore, while iPSC-derived
neurons that express many inhibitory cortical interneuron
subtype markers can be readily generated, these may not
represent mature or inclusive subtypes, by comparison
with those present in fetal brain. Finally, while threedimensional (3D) cortical organoids are now in use, these
represent substantially more complex and heterogeneous
mixtures of different neural cell types, and so were not
incorporated into our cross-manuscript comparison (Lancaster et al., 2013; Sidhaye and Knoblich, 2021). In summary, it is important for studies to build on patient clinical
phenotypes and draw comparisons between fetal- and
iPSC-derived neuronal cell types.
Differentiation of cortical neurons from iPSCs
Protocols for generating iPSC-derived neurons in vitro to
study IDDs involve manipulating growth factor signaling
to mimic developmental cues or, more recently, inducing
neurons directly from iPSCs by overexpressing neurogenic
transcription factors (TFs) for cell fate conversion. Each
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protocol has multiple intervention points that vary between laboratories, researchers, or experiments, resulting
in differential efficiencies with which neurons are generated, and in their characteristics, maturation, and functionality (Figure 3; Tables S4, S5, and S6). Variation must be
documented and controlled to enable reproducible results
and post hoc meta-analyses, especially to compare data
across different IDDs or studies. We summarize technical
variables for protocol standardization and benchmarking
of iPSC-derived neurons.
In vitro iPSC differentiation protocols endeavor to mimic
spatial signals present during brain specification and
patterning in vivo (Campbell, 2003; Gaspard et al., 2008;
Watanabe et al., 2005). iPSCs transition into NPCs before
maturing into neurons. When handled and monitored
properly, NPCs can be expanded and/or cryopreserved,
which is advantageous for assays requiring large cell
numbers, and minimizes differentiation batch effects between assays. The most widely used strategy to derive neural ectoderm from iPSCs involves inhibiting SMAD TFs
acting downstream of the Activin/Nodal and bone
morphogenetic protein (BMP) transforming growth factor
b (TGF-b) signaling pathways (so-called dual SMAD inhibition [Chambers et al., 2009]). Further modulating
morphogen signaling, including SHH and WNT, specifies
NPCs with different dorsoventral and anterior-posterior
regional identities, resembling progenitors found in
different locations of the developing brain. NPCs can
then be differentiated into cortical neurons that are
predominantly glutamatergic without morphogens, or
differentiated into GABAergic cortical neurons or specific
interneuron subtypes with particular morphogens (Figure 3; Tables S4, S5, and S6).
Most iPSC differentiation protocols promote NPC cell cycle exit to generate neurons (Borghese et al., 2010; Ogura
et al., 2013). If a relatively homogeneous neuronal culture
is required for downstream analyses, some protocols also
incorporate additional steps to eliminate proliferating progenitors and/or isolate mature neurons from the culture,
including adding AraC (cytarabine) to kill dividing cells or
purifying neurons expressing cell surface markers. Maturing
neurons remains a major challenge, as these cells typically
resemble human fetal neurons rather than those of later
developmental stages (Handel et al., 2016). Co-culturing
iPSC-derived neurons on astrocyte feeders (mouse/rat or human) can promote functional maturation (Johnson et al.,
2007). Maturing iPSC-derived neurons may require more
complex culture conditions involving more than one
neuronal subtype and glial population. Some researchers
address this challenge by using 3D organoid cultures, but
these neurons are still not fully mature, mimicking neurons
in second trimester fetal brain (Amiri et al., 2018; Kaya et al.,
2019; Velasco et al., 2019).

Key technical variables
Many differentiation protocols are used to generate cortical
excitatory neurons and cortical interneurons. Key technical
variables (detailed in Tables S4 and S5) include signaling
cues/morphogens and basal media, time course, 3D versus
monolayer culture, molecular markers used to benchmark
specification and differentiation, efficiency with which
NPCs and neurons express these markers, and assays used
to assess functional neuronal properties. Technical variability influences the specificity, efficiency, and timing of
patterning, and/or affects characteristics of the resulting
NPCs and neurons. For example, for cortical excitatory
NPC specification, some protocols modulate only BMP
signaling (Griesi-Oliveira et al., 2015), while most modulate
both BMP and Activin/Nodal TGF-b signaling (Table S4).
Likewise, current protocols for specifying cortical interneuron NPCs use variable timing and regimens for SHH
modulation (Liu et al., 2013; Maroof et al., 2013; Meganathan et al., 2017; Nicholas et al., 2013) (Table S5). Even protocols that ostensibly modulate the same signaling pathways over the same time frame vary, with some using
recombinant proteins while others use small-molecule agonists or antagonists (Tables S4 and S5). Finally, vendor and
lot-to-lot variability, as well as variable toxicity, may effect
experimental outcomes (Zhang et al., 2012). These variables
can be addressed by fully disclosing materials, including
vendor and catalog number, and providing detailed differentiation protocols with a clearly annotated timeline for
experimental procedures.
Another fundamental variable involves whether cells undergo patterning as a plated monolayer (ML), a floating 3D
embryoid body (EB), or an adherent, plated EB (aEB), during either NPC specification and/or neuronal differentiation (Tables S4 and S5). While EB methods arguably more
closely mimic cell-cell interactions that occur in the developing neural tube, EBs can be heterogeneous. Moreover, as
the signaling mechanisms in each paradigm are not fully
appreciated, there may be subtle differences in performance, such that it is critical to benchmark the neuronal
outcome.
Induced neurons: Bypassing development
Overexpressing neurogenic TFs can directly convert iPSCs
into induced neurons or "iNs" (Pang et al., 2011; Xu et al.,
2015). Commonly used TFs to produce cortical excitatory
iNs include Neurogenin-2 (NGN2), NGN1, and NEUROD1
(Tables S6). Similarly, GABAergic neurons or astrocytes can
also be effectively induced using other TFs (Araujo et al.,
2018; Canals et al., 2018; Yang et al., 2017). iNs are relatively homogeneous (e.g., >90% neurons), and reach later
developmental stages more quickly than developmentbased differentiation protocols. Thus, iNs are useful for applications like high-content imaging or high-throughput
screening, which require large numbers of neurons with
Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021 1451
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Figure 3. Technical variables that differ by laboratory and protocol during generation of neurons from iPSCs
(A and B) Variables that differ during specification and differentiation of iPSCs into (A) glutamatergic cortical excitatory neurons and (B)
GABAergic cortical inhibitory neurons are shown. These include signaling cues/additives, basal media, culture conditions, and whether
differentiation is conducted in monolayer (ML), or adherent or non-adherent embryoid body (aEB/EB) culture.
(C) Variables that differ during generation of cortical excitatory neurons from iPSCs by NGN2 overexpression. This figure summarizes data
from studies assessed in Tables S4, S5, and S6. Abbreviations and definitions of terms are in Table S8. Scale bars, 50 mm in (A and B) and
130 mm in (C).
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low batch-to-batch variability. However, since most iN protocols are designed to generate a single homogeneous
neuronal subtype, iNs may require co-culturing to facilitate
maturation and functionality. Furthermore, as published
protocols used by various laboratories differ in multiple
ways, the resulting iNs may also differ (Table S6).
Comprehensive analysis of iNs, including single-cell
sequencing, is needed to define their identity and developmental stage, and to determine whether these cells
resemble neurons in vivo. When studying IDDs with patient-derived iNs, exogenously expressing a master transcriptional regulator of neurogenesis, such as NGN2 may
override and mask IDD-related defects in neuronal development, particularly those occurring upstream of NGN2
activities (Wilkinson et al., 2013). Moreover, since most
IDDs involve altered neurodevelopment, some phenotypes
may only be detected by differentiating iPSCs through an
NPC intermediate. As iN protocols involve a significantly
shortened progenitor stage, these protocols are not suitable
for characterizing NPC-specific anomalies and can
confound use of iNs to define IDD-linked cellular phenotypes (Schafer et al., 2019).
TF overexpression remodels the epigenetic landscape.
Coupled with antibiotic selection, iNs exhibit lower
batch-to-batch and line-to-line variability than neurons
derived by modulating signaling. However, similar
technical variables (e.g., iPSC quality, media conditions,
extracellular matrix environment, and cell organization)
likewise impact differentiation propensity and cell identity.
For example, using both dual SMAD inhibition-mediated
differentiation media and NGN2 overexpression in concert
increases generation of mature neurons (Nehme et al.,
2018). Single-cell sequencing also revealed molecular heterogeneity and challenges the notion that iNs are homogeneous. Since iNs can still sense extrinsic signals, it is
perhaps not surprising that cell fate can be influenced by
both culture conditions and TF reprogramming. Furthermore, different expression vector integration sites can
cause variable expression of neurogenic TFs, increasing iN
heterogeneity. Use of genome editing to introduce an
inducible TF expression construct into genomic safe harbor
loci (e.g., AAVS1) can overcome this shortcoming.
Several unique variables apply to these transcription factor-based protocols (Table S6). Similar to growth factormediated differentiation, cell-seeding density profoundly
affects iN maturation and health. Viral titer and transduction efficiency, antibiotic selection dosage and time frame
(if used), and doxycycline dosage and time frame to induce
TF overexpression must all be optimized to minimize iPSC
toxicity and generate robust iN populations. While activities of key TFs are expected to be largely conserved between species, direct comparisons have not been made,
complicating comparisons between studies using human

versus mouse NGN2 overexpression. Moreover, tetracycline-inducible transcriptional activation can exhibit leaky
basal transcription in an uninduced state, potentially
compromising iPSC pluripotency (Costello et al., 2019;
Tian et al., 2009). Therefore, it is important to select lines
with low basal TF expression when establishing iPSC lines
transduced with iN factors and to monitor spontaneous
differentiation when culturing uninduced iPSCs.
Recommendations and benchmarks to address variability
Given many potential sources of variability, it is essential to
benchmark iPSC quality, efficiency of progenitor specification, regional progenitor character, neuronal differentiation efficiency, final cell identity and culture composition,
and neuronal maturity and functionality (Muratore et al.,
2014; Tao and Zhang, 2016; Topol et al., 2015). Recommendations for best practices in data collection, QC, and
benchmarking are summarized in Table 1, and a template
for data documentation is provided in Table S7.
Genetic abnormalities can arise during reprogramming,
passaging, or genome editing of iPSCs. Therefore, cell line
authentication and quality control for pluripotency and
genome stability are essential. Verification of cell line identity with the patient-derived sample by short tandem
repeat (STR) analysis is required, as is validation of stem
cell marker expression. Trilineage differentiation potential
confirms iPSC pluripotency. Importantly, accumulation of
common chromosomal abnormalities should be closely
monitored as aneuploidy (most frequently of chromosomes 12, 17, 20, and X) is common (Assou et al., 2020;
Taapken et al., 2011). At a minimum, G-banded chromosome analysis should be carried out immediately after
iPSC derivation, after each cell expansion for banking,
and after every 5–10 passages during culture (Martins-Taylor et al., 2011; McIntire et al., 2020). In addition, a recent
study has shown similar numbers of TP53 mutations in
cells grown with and without feeder cells (Merkle et al.,
2017), but further studies are required. Clump passaging
and avoidance of enzymatic dissociation when culturing
iPSCs is advisable, as dissociation to single cells may select
for the best adapted cells, contributing to genomic variation (Bai et al., 2015; Garitaonandia et al., 2015). It is also
advisable to track each line’s passage number and avoid
working with lines at >40 passages when aneuploidy and
other mutations are more likely to arise (Martins-Taylor
et al., 2011; McIntire et al., 2020; Taapken et al., 2011).
For this reason, it is crucial to expand and cryopreserve
large numbers of vials of working stocks at low passage
number for each iPSC line. Furthermore, CNVs are present
as low-frequency somatic genomic variants in parental fibroblasts and manifested in the corresponding iPSC lines
due to the colonies’ clonal origin (Abyzov et al., 2012).
Experimental design should account for differences between clonal lines derived from the same patient by
Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021 1453
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replicating findings across at least two independent clonal
lines, with more than four patient/control pairs when
available (biological replicates), and more than three independent differentiation batches (technical replicates) per
experiment (Germain and Testa, 2017). For phenotyping
NPCs and neurons derived from multiple iPSC lines, it is
important to differentiate each, if not all, patient/control
pairs simultaneously to minimize experimental variability.
It is also ideal to derive iPSCs from the same somatic cell
type via the same reprogramming method, and to maintain
these in the same manner, to reduce potential variability.
Furthermore, for phenotyping in small well format (96or 384-well), robotic liquid handling and electronic
pipettes with speed and volume control can decrease
well-to-well variability.
For neural differentiation, pilot testing of reagents
should be conducted and, whenever possible, the same
validated lots of reagents throughout a set of experiments
should be used. Once NPCs are generated, in addition to
gene expression, they should be assessed for the desired
NPC identity (e.g., >80% of cells expressing PAX6 or
NKX2-1 for excitatory and inhibitory NPCs, respectively)
by fluorescence-activated cell sorting (FACS) or immunocytochemistry (Tables S4 and S5). If NPCs or transduced iPSCs
for generating iNs are cultured, passage number and
culturing duration should be limited to avoid cell state
drift. Once neurons have been differentiated, the efficiency
of differentiation, neuron maturity, and functional properties should be assessed, starting with qPCR or RNA
sequencing (bulk or single cell). Next, it is standard practice
to report both the overall percentage of neurons (e.g., expressing TUJ1 and MAP2) and percentage expressing
markers of the neuronal subtype of interest (e.g., VGlut
or VGAT for excitatory and inhibitory neurons, respectively; Tables S4 and S5). If purification approaches, such
as FACS or microbead-bound antibodies, are used to isolate
cells during differentiation, a detailed timeline for differentiation, cell purification, and experimental assays should
be reported. Finally, functional assessment by patch-clamp
or multi-electrode array should be reported to characterize
electrophysiological properties of the neurons. In sum,
quantitative and qualitative assessment of the cell population is required throughout differentiation. Genetic and
epigenetic background can modify not only the neuronal
differentiation efficiency, but also the timing of neuronal
maturity and acquisition of subtype identity and functional properties, even within excitatory or inhibitory
neuron populations. Therefore, comprehensive analyses
utilizing multiple neuronal markers, in combination with
appropriate iPSC controls, are necessary to distinguish an
IDD mutation-associated phenotype.
Quantitative data should be supported by adequate statistics. As a best practice, statistical tests should be per1454 Stem Cell Reports j Vol. 16 j 1446–1457 j June 8, 2021

formed with at least four independent biological replicates
(iPSCs from different individuals) (Germain and Testa,
2017). ISSCR guidelines encourage some journals (e.g.,
Stem Cell Reports) to require data from two to three patients and two to three controls, with two to three clones
per donor analyzed. These numbers may be smaller when
studying rare diseases or when using isogenic pairs of
iPSC lines. More patients may be needed when studying
polygenic disorders, unless a rigorous patient/control selection strategy is used.
Conclusion
Patient-derived iPSCs provide a unique and powerful
model to study IDD etiology, both incorporating complex
genetic contributors to IDDs in individual patients and
recapitulating aspects of human brain development otherwise inaccessible to experimentation. The issues we raise
are broadly applicable to other brain disorders. With
knowledge accumulated from prior studies and advances
in technology, we now have a wide repertoire of tools.
Diverse techniques can sometimes unveil serendipitous
discoveries that are informative, but the data are then not
easily accessible and/or cross-comparable. Therefore, it is
important to implement standard quality control measures
and to methodically document experimental design
and outcomes in publications. Such standards enable
meta-analysis across groups and/or across different IDDs
to identify commonly affected pathways for developing interventions. Adherence to these standards requires
increased resources, and so we recommend that journal editors provide additional time for experimentation and that
funding agencies provide additional funding to fortify the
reproducibility of future studies. Now, more than ever, the
stem cell research community needs to develop shared
standards, approaches, and benchmarks to ensure rigor
and reproducibility in stem cell-based IDD research, so
that these experimental systems can be used to define
reproducible alterations of neurodevelopment and neural
cell function linked to IDDs and to assess potential avenues
for diagnosis and treatment.
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